A detailed history of High Point Advisor Group LLC transactions in Biogen Inc. stock. As of the latest transaction made, High Point Advisor Group LLC holds 1,553 shares of BIIB stock, worth $227,467. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,553
Previous 1,899 18.22%
Holding current value
$227,467
Previous $440,000 31.59%
% of portfolio
0.02%
Previous 0.02%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$189.07 - $236.8 $65,418 - $81,932
-346 Reduced 18.22%
1,553 $301,000
Q2 2024

Aug 08, 2024

SELL
$190.52 - $236.72 $1,524 - $1,893
-8 Reduced 0.42%
1,899 $440,000
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $2,120 - $2,677
-10 Reduced 0.52%
1,907 $411,000
Q4 2023

Mar 26, 2024

BUY
$222.59 - $267.94 $426,705 - $513,640
1,917 New
1,917 $496,000
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $230,299 - $273,868
-1,228 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $18,394 - $23,988
65 Added 5.59%
1,228 $348,000
Q2 2021

Jul 29, 2021

BUY
$259.0 - $414.71 $7,252 - $11,611
28 Added 2.47%
1,163 $403,000
Q1 2021

Apr 12, 2021

SELL
$242.95 - $284.63 $2,915 - $3,415
-12 Reduced 1.05%
1,135 $304,000
Q4 2020

Feb 10, 2021

BUY
$236.26 - $355.63 $23,389 - $35,207
99 Added 9.45%
1,147 $309,000
Q3 2020

Nov 06, 2020

BUY
$264.77 - $305.71 $30,183 - $34,850
114 Added 12.21%
1,048 $345,000
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $9,829 - $13,016
38 Added 4.24%
934 $247,000
Q1 2020

May 01, 2020

BUY
$268.85 - $341.04 $169,375 - $214,855
630 Added 236.84%
896 $266,000
Q1 2020

Apr 27, 2020

SELL
$268.85 - $341.04 $162,116 - $205,647
-603 Reduced 69.39%
266 $896,000
Q4 2019

Feb 13, 2020

BUY
$220.06 - $304.07 $12,763 - $17,636
58 Added 7.15%
869 $249,000
Q3 2019

Nov 12, 2019

SELL
$217.44 - $243.88 $7,392 - $8,291
-34 Reduced 4.02%
811 $237,000
Q2 2019

Aug 15, 2019

SELL
$219.29 - $241.72 $16,008 - $17,645
-73 Reduced 7.95%
845 $196,000
Q1 2019

May 08, 2019

SELL
$216.71 - $338.96 $480,446 - $751,474
-2,217 Reduced 70.72%
918 $210,000
Q4 2018

Feb 20, 2019

BUY
$278.5 - $352.75 $75,752 - $95,948
272 Added 9.5%
3,135 $1.04 Million
Q3 2018

Oct 24, 2018

BUY
$293.51 - $383.83 $667,735 - $873,213
2,275 Added 386.9%
2,863 $903,000
Q2 2018

Aug 20, 2018

SELL
$257.52 - $306.91 $51,504 - $61,382
-200 Reduced 25.38%
588 $202,000
Q1 2018

Jun 11, 2018

SELL
$260.13 - $367.91 $9,364 - $13,244
-36 Reduced 4.37%
788 $239,000
Q4 2017

Feb 15, 2018

BUY
$307.64 - $344.58 $6,152 - $6,891
20 Added 2.49%
824 $261,000
Q3 2017

Nov 06, 2017

BUY
$281.15 - $329.69 $226,044 - $265,070
804
804 $249,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track High Point Advisor Group LLC Portfolio

Follow High Point Advisor Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.